Cargando…

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis

OBJECTIVE: The aim of this study was to investigate whether the nuclear receptor farnesoid X receptor (FXR) could regulate FNDC5/Irisin expression and the role of Irisin in hyperlipidemia and atherosclerosis in ApoE-/- mice. METHODS AND RESULTS: We treated primary human hepatocytes, HepG2 cells, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hong, Shen, Jing, Wu, Tong, Kuang, Jiangying, Liu, Qinhui, Cheng, Shihai, Pu, Shiyun, Chen, Lei, Li, Rui, Li, Yanping, Zou, Min, Zhang, Zhiyong, Jiang, Wei, Qu, Aijuan, He, Jinhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546903/ https://www.ncbi.nlm.nih.gov/pubmed/31191305 http://dx.doi.org/10.3389/fphar.2019.00548

Ejemplares similares

Inhibition of 5-Lipoxygenase in Hepatic Stellate Cells Alleviates Liver Fibrosis
por: Pu, Shiyun, et al.
Publicado: (2021)

Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury
por: Pu, Shiyun, et al.
Publicado: (2019)

PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy
por: Li, Yanping, et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Calculus Bovis Sativus Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis
por: Xiang, Dong, et al.
Publicado: (2019)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
por: Zhou, Mengjiao, et al.
Publicado: (2022)

Paeoniflorin alleviates 17α-ethinylestradiol-induced cholestasis via the farnesoid X receptor-mediated bile acid homeostasis signaling pathway in rats
por: Wang, Rulin, et al.
Publicado: (2022)

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
por: Zhu, Yanlin, et al.
Publicado: (2020)

Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis
por: Li, Yanping, et al.
Publicado: (2019)

Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling
por: Paraiso, Ines L., et al.
Publicado: (2021)

Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
por: Tang, Kaijia, et al.
Publicado: (2022)

Feeding-induced hepatokine, Manf, ameliorates diet-induced obesity by promoting adipose browning via p38 MAPK pathway
por: Wu, Tong, et al.
Publicado: (2021)

Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
por: Prawitt, Janne, et al.
Publicado: (2011)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Baicalin Protects Against 17α-Ethinylestradiol-Induced Cholestasis via the Sirtuin 1/Hepatic Nuclear Receptor-1α/Farnesoid X Receptor Pathway
por: Yang, Jinyu, et al.
Publicado: (2020)

Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases
por: Festa, Carmen, et al.
Publicado: (2017)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

The Role of Sirt6 in Obesity and Diabetes
por: Kuang, Jiangying, et al.
Publicado: (2018)

Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo
por: Hassan, Haider M., et al.
Publicado: (2022)

Low FNDC5/Irisin expression is associated with aggressive phenotypes in gastric cancer
por: Xu, Luyun, et al.
Publicado: (2022)

Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN
por: LIU, JUN, et al.
Publicado: (2014)

Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway
por: Zhao, Yingnan, et al.
Publicado: (2021)

Novel Therapeutic Targets in Liver Fibrosis
por: Zhang, Jinhang, et al.
Publicado: (2021)

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target
por: Chen, Jiahao, et al.
Publicado: (2022)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Irisin, Energy Homeostasis and Male Reproduction
por: Sengupta, Pallav, et al.
Publicado: (2021)

CRELD2, endoplasmic reticulum stress, and human diseases
por: Tang, Qin, et al.
Publicado: (2023)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
por: Li, Guodong, et al.
Publicado: (2015)

Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis
por: Yu, Junhui, et al.
Publicado: (2020)

SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway
por: Zhang, Jinhang, et al.
Publicado: (2018)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ej1sllsfc9787r197cg64ttdkr